Shukla Sath 4
4 · Spero Therapeutics, Inc. · Filed Aug 30, 2023
Insider Transaction Report
Form 4
Shukla Sath
CEO & President
Transactions
- Sale
Common Stock
2023-08-28$1.26/sh−1,854$2,336→ 576,663 total - Sale
Common Stock
2023-08-29$1.30/sh−4,163$5,412→ 572,500 total
Footnotes (2)
- [F1]The reported transaction is a sale of common stock effected to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs") that were granted to the Reporting Person on August 26, 2021 pursuant to a "sell to cover" provision included in the RSU Agreement.
- [F2]The reported transaction is a sale of common stock pursuant to a preexisting 10b5-1 plan upon the vesting of RSUs that were granted to the Reporting Person on August 26, 2021.